Opendata, web and dolomites

PrevictDrugs SIGNED

Smartphone Measured Eye-Based Digital Biomarkers for Drug Use Detection

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 PrevictDrugs project word cloud

Explore the words cloud of the PrevictDrugs project. It provides you a very rough idea of what is the project "PrevictDrugs" about.

kontigo    mood    monitoring    asked    screenings    yield    extreme    tools    settings    patient    eye    caregivers    add    pupil    routes    smartphone    pupillometry    distance    fast    thing    instead    prioritisation    previct    pharmacodynamically    designed    interventions    hazard    ai    patients    addictive    eyes    reactions    constitute    voluntary    drive    ab    privacy    instant    disorders    iot    unbound    drug    portal    communication    worldwide    treatments    module    validating    acceptance    medical    risks    abuse    commercialisation    combine    care    addiction    ing    clinical    correct    healthcare    innovative    internet    cravings    drugs    efficient    outcomes    ehealth    solution    biomarkers    transform    personal    gambling    device    nearly    sophisticated    relapse    suffering    app    reactive    instantly    disruptive    platform    global    continuous    cloud    prepare    cameras    daily    gaining    suffer    video    market    digitalisation    therapy    personalised    illicit    complete    self    convenience    record    million    time    place    proactive    sobriety    efficiency    alcohol   

Project "PrevictDrugs" data sheet

The following table provides information about the project.

Coordinator
KONTIGO CARE AB 

Organization address
address: PAVEL SNICKARES GRAND 12
city: UPPSALA
postcode: 753 20
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Sweden [SE]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-09-01   to  2020-02-29

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    KONTIGO CARE AB SE (UPPSALA) coordinator 50˙000.00

Map

Leaflet | Map data © OpenStreetMap contributors, CC-BY-SA, Imagery © Mapbox

 Project objective

Drug addiction is a global problem; nearly 30 million illicit drug users worldwide suffer from problematic drug use. Kontigo Care AB is developing an innovative medical device – Previct Drugs - a robust, app-based, eHealth-platform for place unbound, continuous, voluntary, self-monitoring of drug use. It will constitute an add-on to Kontigo Care’s current eHealth offer developed for management of other addictive disorders (alcohol abuse and hazard gambling). Using smartphone cameras, patients suffering from drug addiction, will be identified, and asked to record a 10 s long video of their eyes. Analysis of eye biomarkers associated with pharmacodynamically induced pupil reactions (pupillometry) will yield instant results on drug use/sobriety. Our unique, disruptive Internet of Thing (IoT)-based approach is designed to combine continuous monitoring of drug use and daily mood/cravings, with communication tools aimed at improving the impact of distance care. Real-time results become instantly available to caregivers through our cloud-based Care Portal, allowing fast interventions and correct patient prioritisation. This eHealth solution will drive healthcare digitalisation resulting in extreme cost-efficiency of out-patient treatments as well as convenience and complete privacy during drug screenings. A sophisticated AI-system will assess personal risks of relapse and transform addiction management to become proactive instead of reactive. This approach has the potential to enhance personalised therapy outcomes by ensuring that help can be provided fast to the patients who need it the most. The project objective is to prepare for commercialisation of the Previct Drugs module by determining the most efficient routes for gaining clinical and market acceptance by validating the product in clinical settings.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PREVICTDRUGS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PREVICTDRUGS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Colourganisms (2020)

Microbial production of custom-made, pure and sustainable anthocyanins

Read More  

IMPACT (2019)

Improving DNA Analysis for Correct Healthcare

Read More  

EASY-Diabetes (2019)

Individualised and Equitable Care of Type 2 Diabetes

Read More